Identification of an opioid peptide secreted by rat embryonic mixed brain cells as a promoter of macrophage migration.
Conditioned media from embryonic mixed cells from the rat brain were used in a chemotaxis assay to look for potential chemotactic activity which could account for the infiltration of the developing central nervous system (CNS) by macrophage precursors. The most potent chemotactic activity was found in the conditioned medium from E17 mixed brain cells (E17-CM). Based upon checkerboard analysis, this activity was shown to be chemotactic rather than chemokinetic. This chemoattraction was not restricted to brain macrophages (BM) because it was as pronounced on bone marrow-derived macrophages. The implication of a peptide compound in this activity was suggested by its resistance to heat as well as acid treatments, and by its sensitivity to aminopeptidase M digestion. In agreement with the opioid nature of the peptide, not only naloxone, but also the delta opioid receptor antagonist ICI-174 reduced the migration of BM in response to E17-CM by 60%. This migratory activity was no longer effective when pertussis toxin-treated BM were used. When the chemotactic effects of selective opioid agonists were compared to that of E17-CM, DPDPE, the delta agonist, was the most efficient in attracting BM. Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis indicated that delta as well as other known opioid receptors were expressed in both BM and E17 mixed brain cells. Finally, a Met-enkephalin-like reactivity was found by RIA in the E17-CM. Altogether, these observations suggest that a delta-like opioid peptide released from embryonic mixed brain cells could be responsible for the infiltration of the developing CNS by macrophages precursors.
Calvo
C F
CF
Chaire de Neuropharmacologie, INSERM U114, Collège de France, 11 Place Marcelin Berthelot, 75231 Paris CEDEX 05, France. charles-felix.calvo@college-de-france.fr
Cesselin
F
F
Gelman
M
M
Glowinski
J
J
D000701:Analgesics, Opioid / Q000494:pharmacology; D000818:Animals; D001921:Brain / Q000166:cytology / Q000196:embryology*; D002478:Cells, Cultured; D002634:Chemotaxis, Leukocyte / Q000187:drug effects / Q000502:physiology*; D017077:Culture Media, Conditioned / Q000494:pharmacology; D020881:Enkephalin, D-Penicillamine (2,5)- / Q000494:pharmacology; D018507:Gene Expression Regulation, Developmental; D008264:Macrophages / Q000166:cytology*; D017628:Microglia / Q000166:cytology*; D009270:Naloxone / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D015345:Oligonucleotide Probes; D009842:Oligopeptides / Q000494:pharmacology; D018847:Opioid Peptides / Q000032:analysis / Q000378:metabolism*; D012333:RNA, Messenger / Q000032:analysis; D051381:Rats; D017465:Receptors, Opioid, delta / Q000037:antagonists & inhibitors / Q000235:genetics; D013234:Stem Cells / Q000166:cytology
D000701:Analgesics, Opioid; D017077:Culture Media, Conditioned; D009292:Narcotic Antagonists; D015345:Oligonucleotide Probes; D009842:Oligopeptides; D018847:Opioid Peptides; D012333:RNA, Messenger; D017465:Receptors, Opioid, delta; D009270:Naloxone; D020881:Enkephalin, D-Penicillamine (2,5)-; C092825:ICI 174865